Sanofi (SAN.PA)
| Previous close | 88.85 |
| Open | 89.06 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 88.78 - 89.65 |
| 52-week range | 80.60 - 105.18 |
| Volume | |
| Avg. volume | 1,364,447 |
| Market cap | 111.567B |
| Beta (5Y monthly) | 0.45 |
| PE ratio (TTM) | 20.79 |
| EPS (TTM) | 4.30 |
| Earnings date | 25 Apr 2024 |
| Forward dividend & yield | 3.76 (4.23%) |
| Ex-dividend date | 13 May 2024 |
| 1y target est | 105.70 |
BloombergSanofi Asks Banks to Pitch for $20 Billion OTC Spinoff
(Bloomberg) -- French drugmaker Sanofi has asked banks to pitch for roles on the separation of its consumer-health business, according to people familiar with the matter, one of the biggest deals likely to happen in Europe this year. Most Read from BloombergTaylor Swift Is Proof That How We Critique Music Is BrokenBiden’s New Chopper Is Demoted After Scorching White House LawnTesla Speeds Cheaper EV Plans, Calming Fears Over StrategyBillionaire Pinaults Fight to Pull Gucci Off the Discount RackR
ZacksSanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study
Sanofi's (SNY) BTK inhibitor, rilzabrutinib, demonstrates durable platelet response in the phase III LUNA 3 study in adult patients with immune thrombocytopenia.
GlobeNewswirePress Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Pivotal data from the first phase 3 study of a BTKi in immune thrombocytopenia (ITP) underscore the potential of rilzabrutinib to provide a clinically meaningful benefit to patients living with ITPRegulatory submissions in the US and EU anticipated by year-endRilzabrutinib is one of 12 potential medicines and vaccines in Sanofi’s robust immunology pipeline and a testament to Sanofi’s ability to successfully accele
